You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,737,529


✉ Email this page to a colleague

« Back to Dashboard


Title:Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
Abstract: Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.
Inventor(s): Sackler; Richard (Greenwich, CT)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Filing Date:Mar 18, 2016
Application Number:15/074,052
Claims:1. A method of preparing a pharmaceutical dosage form comprising combining a therapeutically effective amount of an opioid analgesic, an opioid antagonist and an irritant in a pharmaceutical dosage form, wherein the irritant is in an effective amount to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

2. The method of claim 1, wherein said irritant is at least partially interdispersed with the opioid analgesic.

3. A method of treating abuse of an oral dosage form of an opioid analgesic comprising: preparing the dosage form with an analgesically effective amount of an opioid analgesic, an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

4. The method of claim 3, wherein the irritant comprises from about 0.00125% to about 50% by weight of the dosage form.

5. The method of claim 4, wherein the irritant comprises from about 1 to about 7.5% by weight of the dosage form.

6. The method of claim 5, wherein the irritant comprises from about 1 to about 5% by weight of the dosage form.

7. The method of claim 3, wherein the opioid antagonist is in an amount to attenuate a side effect of said opioid analgesic selected from the group consisting of anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, tolerance, and a combination of any of the foregoing.

8. The method of claim 3, wherein the opioid antagonist comprises naloxone or a pharmaceutically acceptable salt thereof.

9. The method of claim 3, wherein the opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.

10. The method of claim 3, wherein the weight ratio of the opioid agonist and the opioid antagonist is from about 1:1 to about 50:1.

11. The method of claim 3, wherein the opioid analgesic is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, buprenorphine, fentanyl and derivatives thereof, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, levorphanol, salts thereof, and mixtures thereof.

12. The method of claim 11, wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

13. The method of claim 1, wherein the opioid analgesic is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, buprenorphine, fentanyl and derivatives thereof, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, levorphanol, salts thereof, and mixtures thereof.

14. The method of claim 13, wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

15. The method of claim 1, wherein the opioid antagonist comprises naloxone or a pharmaceutically acceptable salt thereof.

16. The method of claim 1, wherein the opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.

17. The method of claim 1, wherein the opioid antagonist is in an amount to attenuate a side effect of said opioid analgesic selected from the group consisting of anti-analgesia, hyperalgesia, hyperexcitability, physical dependence, tolerance, and a combination of any of the foregoing.

18. The method of claim 1, wherein the irritant comprises from about 0.00125% to about 50% by weight of the dosage form.

19. The method of claim 18, wherein the irritant comprises from about 1 to about 7.5% by weight of the dosage form.

20. The method of claim 19, wherein the irritant comprises from about 1 to about 5% by weight of the dosage form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.